Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Schoot, Reineke A ^a   van Dalen, Elvira C ^a   van Ommen, Cornelia H ^a   van de Wetering, Marianne D ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIBIOTIC AGENT; UROKINASE; ANTIINFECTIVE AGENT; FIBRINOLYTIC AGENT; TOPICAL ANTIINFECTIVE AGENT;

ADVERSE EVENT; ANTIBIOTIC THERAPY; BLOOD CULTURE; CANCER PATIENT; CATHETER INFECTION; CHILD; CHILDHOOD CANCER; CLINICAL OUTCOME; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; INTENSIVE CARE; INTERMETHOD COMPARISON; MEDICAL DEVICE COMPLICATION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; REVIEW; SEPSIS; SYSTEMATIC REVIEW; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETER; DRUG COMBINATION; INDWELLING CATHETER; NEOPLASMS; PROCEDURES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CATHETER-RELATED INFECTIONS; CATHETERS, INDWELLING; CENTRAL VENOUS CATHETERS; CHILD; DRUG THERAPY, COMBINATION; ETHANOL; FIBRINOLYTIC AGENTS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84891685844     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008975.pub2     Document Type: Review

References (146)

1. Atkinson JB, Chamberlin K, Boody BA. A prospective randomized trial of urokinase as an adjuvant in the treatment of proven Hickman catheter sepsis. Journal of Pediatric Surgery 1998;33:714-6.
2. Dannenberg C, Bierbach U, Rothe A, Beer J, Korholz D. Ethanol-lock technique in the treatment of bloodstream infections in pediatric oncology patients with Broviac catheter. Journal of Pediatric Hematology/Oncology 2003;25:616-21.
3. La Quaglia MP, Caldwell C, Lucas A, Corbally M, Heller G, Steinherz L, et al.A prospective randomized double-blind trial of bolus urokinase in the treatment of established Hickman catheter sepsis in children. Journal of Pediatric Surgery 1994;29:742-5.
4. Abdelkefi A, Achour W, Othman TB, Ladeb S, Torjman L, Lakhal A, et al.Use of heparin-coated central venous lines to prevent catheter-related bloodstream infection. Journal of Supportive Oncology 2007;5:273-8.
5. Abdelkefi A, Chelli M, Achour W, Romdhane NB, Torjman L, Ladeb S, et al.[Catheter related bloodstream infection in haematological patients: a prospective, randomized study comparing heparin-coated with chlorhexidine and silver sulfadiazine impregnated central venous catheters]. American Society of Hematology Annual Meeting Abstracts, ASH. 2008:1174.
6. Akyüz C, Kpeli S, Yagci-Kpeli B, Bykpamukcu M. Prophylactic taurolidine use in central venous catheters of pediatric cancer patients: A prospective randomized study from single center. Pediatric Blood and Cancer. 2010; Vol. 42nd Congress of the International Society of Pediatric Oncology, SIOP:949.
7. Al-Hathal M, Malmfors G, Garwicz S, Bekassy AN. Port-A-Cath in children during long-term chemotherapy: complications and outcome. Pediatric Hematology and Oncology 1989;6:17-22.
8. Albanese CT, Wiener ES. Venous access in pediatric oncology patients. Seminars in Surgical Oncology 1993;9:467-7.
9. Anoop P, Anjay MA. Towards evidence based medicine for paediatricians. Role of antibiotic line locks in the treatment of infected central venous access devices. Archives of Disease in Childhood 2009;94:556-9.
10. Aquino VM, Sandler ES, Mustafa MM, Steele JW, Buchanan GR. A prospective double-blind randomized trial of urokinase flushes to prevent bacteremia resulting from luminal colonization of subcutaneous central venous catheters. Journal of Pediatric Hematology/Oncology 2002;24:710-3.
11. Arora RS, Roberts R, Eden TOB, Pizer B. Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD007785.pub2]
12. Ascher DP, Shoupe BA, Maybee D, Fischer GW. Persistent catheter-related bacteremia: clearance with antibiotics and urokinase. Journal of Pediatric Surgery 1993;28:627-9.
13. Ashkenazi S, Leibovici L, Samra Z, Konisberger H, Drucker M. Risk factors for mortality due to bacteremia and fungemia in childhood. Clinical Infectious Diseases 1992;14:949-51.
14. Atay AA, Kismet E, Karaoglu A, Kurekc AE, Baysallar M, Koseoglu V, et al.Comparison of cefepime and meropenem use in treatment of neutropenic fever. Gulhane Medical Journal 2004;46:102-5.
15. Attal M, Schlaifer D, Rubie H, Huguet F, Charlet JP, Bloom E, et al.Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. Journal of Clinical Oncology 1991;9:865-70.
16. Averbuch D, Makhoul R, Rotshild V, Weintraub M, Engelhard D. Empiric treatment with once-daily cefonicid and gentamicin for febrile non-neutropenic pediatric cancer patients with indwelling central venous catheters. Journal of Pediatric Hematology/Oncology 2008;30:527-32.
17. Backeljauw PF, Moodie DS, Murphy DJ Jr. High-dose urokinase therapy for the lysis of a central venous catheter-related thrombus in a young patient with Hodgkin's disease. Clinical Pediatrics 1991;30:274-7.
18. Bagnall-Reeb HA, Ruccione K. Management of cutaneous reactions and mechanical complications of central venous access devices in pediatric patients with cancer: algorithms for decision making. Oncology Nursing Forum 1990;17:677-81.
19. Ball LM, Siddal S, van Saenen H. Teicoplanin in home therapy of the terminally ill child. European Journal of Haematology Supplementum 1993;54:14-7.
20. Barriga FJ, Varas M, Potin M, Sapunar F, Rojo H, Martinez A, et al.Efficacy of a vancomycin solution to prevent bacteremia associated with an indwelling central venous catheter in neutropenic and non-neutropenic cancer patients. Medical and Pediatric Oncology 1997;28:196-200.
21. Berger C, Kindli K, Niggli FK, Nadal D. Withholding initial vancomycin in febrile neutropenia despite implanted catheters. European Journal of Pediatrics 2004;163:422-3.
22. Beutel K, Simon A. Diagnostics and management of central venous line infections in pediatric cancer patients [Diagnostik und therapie katheter-assoziierter infektionen in der pädiatrischen onkologie]. Klinische Padiatrie 2005;217 Suppl 1:S91-100.
23. Boughton BJ, Harris RI, Brown RM, Webberley J, Baglin TP, Jackson N, et al.Gentamicin and low dose piperacillin in febrile neutropenic patients. Journal of Antimicrobial Chemotherapy 1989;24:45-51.
24. Butt T, Afzal RK, Ahmad RN, Hussain I, Anwar M. Central venous catheter-related bloodstream infections in cancer patients. Journal of the College of Physicians and Surgeons Pakistan 2004;14:549-52.
25. Castagnola E, Fioredda F, Barretta MA, Pescetto L, Garaventa A, Lanino E, et al.Bacillus sphaericus bacteraemia in children with cancer: case reports and literature review. Journal of Hospital Infection 2001;48:142-5.
26. Castagnola E, Bandettini R, Lorenzi I, Caviglia I, Macrina G, Tacchella A. Catheter-related bacteremia caused by methicillin-resistant coagulase negative staphylococci with elevated minimal inhibitory concentration for vancomycin. Pediatric Infectious Disease Journal 2010;29(11):1047-8.
27. Cesaro S, Tridello G, Cavaliere M, Magagna L, Gavin P, Cusinato R, et al.Prospective, randomized trial of two different modalities of flushing central venous catheters in pediatric patients with cancer. Journal of Clinical Oncology 2009;27:2059-65.
28. Chamberlain JD, Smibert E, Skeen J, Alvaro F. Prospective audit of treatment of paediatric febrile neutropenia in Australasia. Journal of Paediatrics and Child Health 2005;41:598-603.
29. Chatzinikolaou I, Zipf TF, Hanna H, Umphrey J, Roberts WM, Sherertz R, et al.Minocycline-ethylenediaminetetraacetate lock solution for the prevention of implantable port infections in children with cancer. Clinical Infectious Diseases 2003;36:116-9.
30. Chen WT, Liu TM, Wu SH, Tan TD, Tseng HC, Shih CC. Improving diagnosis of central venous catheter-related bloodstream infection by using differential time to positivity as a hospital-wide approach at a cancer hospital. Journal of Infection 2009;59:317-23.
31. Chen IC, Hsu C, Chien SF, Kao HF, Jhang SY, Chen YC, et al.Characterization of permanently implantable venous port associated bloodstream infection (PABSI) in patients with solid cancers: a case-control study. Multinational Association of Supportive Care in Cancer: International symposium on supportive care in cancer, MASCC. 2011:S262.
32. Cherif H, Bjorkholm M, Engervall P, Johansson P, Ljungman P, Hast R, et al.A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scandinavial Journal of Infectious Diseases 2004;36:593-600.
33. Cherrick I, Kveselis DA, Baesl TJ. Medical management of Candida-infected thrombosis in a pediatric oncology patient. Pediatric Infectious Diseases Journal 1995;14:398-400.
34. Chiu HH, Huang LM, Lee PI, Lee CY. Bacteremia and fungemia in hematological and oncological children with neutropenic fever: two-year study in a medical center. Journal of Microbiology, Immunology and Infection 1998;31:101-6.
35. Daghistani D, Horn M, Rodriguez Z, Schoenike S, Toledano S. Prevention of indwelling central venous catheter sepsis. Medical and Pediatric Oncology 1996;26:405-8.
36. Dias MBS, Habert AB, Borrasca V, Stempliuk V, Ciolli A, Araújo RE, et al.Salvage of long-term central venous catheter during an outbreak of pseudomonas putida and Stenotrophomonas maltophilia infections associated with contaminated heparin catheter-lock solution. Infection Control and Hospital Epidemiology 2008;29(2):1250-30.
37. Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM. Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study. Journal of Clinical Oncology 2004;22:2718-23.
38. Doganis D, Portsidis A, Lebessi E, Bouhoutsou D, Baka M. [Factors related to bloodstream infections in children with cancer]. 39th Congress of the International Society of Pediatric Oncology, SIOP. 2007:483.
39. Douard MC, Arlet G, Leverger G, Paulien R, Waintrop C, Clementi E, et al.Quantitative blood cultures for diagnosis and management of catheter-related sepsis in pediatric hematology and oncology patients. Intensive Care Medicine 1991;17:30-5.
40. Dunn AL, Abshire TC. Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy. Pediatric Blood and Cancer 2008;50:627-9.
41. Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore) 1990;69:296-306.
42. Giacchino M, Bezzio S, Chiapello N, Saracco P, Fagioli F, Caviglia I, et al.Continuous antibiotic infusion for salvage therapy of partially implanted central venous catheter tunnel infections due to staphylococci. Pediatric Blood and Cancer 2007;49:1010-2.
43. Haffar AAM, Rench MA, Ferry GD. Failure of urokinase to resolve Broviac catheter-related bacteremia in children. Journal of Pediatrics 1984;104:256-8.
44. Haimi-Cohen Y, Husain N, Meenan J, Karayalcin G, Lehrer M, Rubin LG. Vancomycin and ceftazidime bioactivities persist for at least 2 weeks in the lumen in ports: simplifying treatment of port-associated bloodstream infections by using the antibiotic lock technique. Antimicrobial Agents and Chemotherapy 2001;45(5):1565-7.
45. Handrup MM, Møller JK, Schrøder H. [Catheter-related bloodstream infections in children with cancer admitted with fever]. 42nd Congress of the International Society of Pediatric Oncology, SIOP. 2010:978.
46. Henrickson KJ, Axtell RA, Hoover SM, Kuhn SM, Pritchett J, Kehl SC, et al.Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial. Journal of Clinical Oncology 2000;18:1269-78.
47. Jones GR, Dillon PW, Bagnall RH, Dillon P, Corless R. Urokinase for prevention of central venous catheter occlusions and infections: results of the Children's Cancer Group Study CCG-S921. Pediatric Research 2001;49:215A.
48. Kalmanti M, Germanakis J, Stiakaki E, Syfridaki C, Christidou A, Tsetis D, et al.Prophylaxis with urokinase in pediatric oncology patients with central venous catheters. Journal of Pediatric Hematology/Oncology 2002;19:173-9.
49. Kaplan SL, Deville JG, Yogev R, Morfin MR, Wu E, Adler S, et al.Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatric Infectious Disease Journal 2003;22:677-86.
50. Kefeli U, Dane F, Yumuk PF, Karamanoglu A, Lyikesici S, Basaran G, et al.Prolonged interval in prophylactic heparin flushing for maintenance of subcutaneous implanted port care in patients with cancer. European Journal of Cancer Care 2009;18:191-4.
51. Kethireddy S, Safdar N. Urokinase lock or flush solution for prevention of bloodstream infections associated with central venous catheters for chemotherapy: a meta-analysis of prospective randomized trials. Journal of Vascular Access 2008;9:51-7.
52. Ketley NJ, Kelsey SM, Newland AC. Teicoplanin and oral ciprofloxacin as outpatient treatment of infective episodes in patients with indwelling central venous catheters and haematological malignancy. Clinical and Laboratory Haematoly 1995;17:71-4.
53. Kinsey SE. Experience with teicoplanin in non-inpatient therapy in children with central line infections. European Journal of Haematology Supplementum 1998;62:11-4.
54. Lee OKE, Johnston L. A systematic review for effective management of central venous catheters and catheter sites in acute care paediatric patients. Worldviews on Evidence-Based Nursing 2005;2:4-13.
55. Ley BE, Jalil N, McIntosh J, Smart A, Wilson M, Foot AB, et al.Bolus or infusion teicoplanin for intravascular catheter associated infections in immunocompromised patients?. Journal of Antimicrobials and Chemotherapy 1996;38:1091-5.
56. Menichetti F, Del Favero A, Bucaneve G, Aversa F, Fiorio M. Using teicoplanin for empiric therapy of febrile neutropenic patients with haematological malignancies. British Journal of Haematology 1990;76 Suppl 2:45-8.
57. Norville R, Horvath B, Lee D, Hyde A, Gregurich M, Hilburn J, et al.[Hub colonization of central line catheter in children with cancer]. American Society of Clinical Oncology Annual Meeting Proceedings, ASCO. 2006:18530.
58. O'Brien AJ, Fenelon LE, O'Dwyer R, McCann SR, Daly PA. A comparative study of latamoxef disodium and gentamicin versus piperacillin and gentamicin in febrile granulocytopenic patients. British Journal of Clinical Practice 1988;42:56-60.
59. Paulus SC, van Saene HK, Hemsworth S, Hughes J, Ng A, Pizer BL. A prospective study of septicaemia on a paediatric oncology unit: a three-year experience at The Royal Liverpool Children's Hospital, Alder Hey, UK. European Journal of Cancer 2005;41:2132-40.
60. Raad I, Darouiche R, Dupuis J, Abi-Said D, Gabrielli A, Hachem R, et al.Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and blood stream infections. A randomized, double-blind trial. Annals of Internal Medicine 1997;127:267-74.
61. Raad I, Escalante C, Hachem RY, Hanna HA, Husni R, Afif C, et al.Treatment of febrile neutropenic patients with cancer who require hospitalization. Cancer 2003;98:1039-47.
62. Reilly AF, McGowan KL. Atypical mycobacterial infections in children with cancer. Pediatric Blood and Cancer 2004;43:698-702.
63. Riikonen P, Saarinen UM, Lahteenoja KM, Jalanko H. Management of indwelling central venous catheters in pediatric cancer patients with fever and neutropenia. Scandinavian Journal of Infectious Diseases 1993;25:357-64.
64. Rubin LG, Shih S, Shende A, Karayalcin G, Lanzkowsky P. Cure of implantable venous port-associated bloodstream infections in pediatric hematology-oncology patients without catheter removal. Clinical Infectious Diseases 1999;29:102-5.
65. Russell L, Craig JI, MacKinlay GA, Eden OB. The use of central venous catheters in paediatric oncology--a cautionary tale. Scottish Medical Journal 1990;35:11-4.
66. Ruud E, Holmstrom H, De Lange C, Hogstad EM, Wesenberg F. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study. Acta Paediatrica 2006;95:1053-9.
67. Safdar A, Rodriguez GH, Raval DS, Bodey GP, Rolston KV. [Polymicrobial bloodstream infections (PBI): An under-realized complication in patients with cancer (2005-2006)]. American Society of Clinical Oncology Annual Meeting Proceedings, ASCO. 2007:19590.
68. Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clinical Infectious Diseases 2006;43:474-84.
69. Sanchez-Munoz A, Aguado JM, Lopez-Martin A, Lopez-Medrano F, Lumbreras C, Rodriguez FJ, et al.Usefulness of antibiotic-lock technique in management of oncology patients with uncomplicated bacteremia related to tunneled catheters. European Journal of Clinical Microbiology and Infectious Diseases 2005;24:291-3.
70. Scheinemann K, Doyle JJ, Allen U, Ethier MC, Dupuis LL, Richardson SE, et al.Contribution of peripheral blood cultures to central catheter cultures in febrile children with cancer. 40th Congress of the International Society of Pediatric Oncology, SIOP. 2008:164.
71. Schierholz JM, Nagelschmidt K, Nagelschmidt M, Lefering R, Yucel N, Beuth J. Antimicrobial central venous catheters in oncology: efficacy of a rifampicin-miconazole-releasing catheter. Anticancer Research 2010;30:1353-8.
72. Schmid L, Feldges A. Implantable devices in patients with haematological diseases. Recent Results in Cancer Research 1991;121:208-14.
73. Schwartz C, Henrickson KJ, Roghmann K, Powell K. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. Journal of Clinical Oncology 1990;8:1591-7.
74. Shivnan JC, McGuire D, Freedman S, Sharkazy E, Bosserman G, Larson E, et al.A comparison of transparent adherent and dry sterile gauze dressings for long-term central catheters in patients undergoing bone marrow transplant. Oncology Nursing Forum 1991;18:1349-56.
75. Simon C, Suttorp M. Results of antibiotic treatment of Hickman-catheter-related infections in oncological patients. Supportive Care in Cancer 1994;2:66-70.
76. Simon A, Bode U, Beutel K. Diagnosis and treatment of catheter-related infections in paediatric oncology: an update. Clinical Microbiology and Infection 2006;12:606-20.
77. Simon A, Ammann RA, Wiszniewsky G, Bode U, Fleischhack G, Besuden MM. Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients. BMC Infectious Diseases 2008;8:102.
78. Simon A, Bode U, Lieber K, Beutel K, Fleischhack G. Review and update of the use of urokinase in the prevention and management of CVAD-related complications in pediatric oncology patients. American Journal of Infection Control 2008;36:54-8.
79. Smith SR, Cheesbrough J, Spearing R, Davies JM. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrobial Agents and Chemotherapy 1989;33:1193-7.
80. Snaterse M, Ruger W, Scholte op Reimer WJM, Lucas C. Antibiotic-based catheter lock solutions for prevention of catheter-related bloodstream infection: a systematic review of randomised controlled trials. Journal of Hospital Infection 2010;75:1-11.
81. Souza Dias MB, Bernardes Habert A, Borrasca V, Stempliuk V, Ciolii A, Araújo RE, et al.Salvage of long-term central venous catheters during an outbreak of Pseudomonas putida and Stenotrophomonas maltophilia infections associated with contaminated heparin catheter-lock solution. Infection Control and Hospital Epidemiology 2008;29(2):125-30.
82. Stoneham S, Skinner R, Johnson G, Millar M. [Diagnosis of central venous access device (CVAD) associated bacteraemia using quantitative 16S rDNA detection]. 39th Congress of the International Society of Pediatric Oncology, SIOP. 2007:511.
83. Tobiansky R, Lui K, Dalton DM, Shaw P, Martin H, Isaacs D. Complications of central venous access devices in children with and without cancer. Journal of Paediatrics and Child Health 1997;33:509-14.
84. Viscoli C. Aspects of infections in children with cancer. Recent Results in Cancer Research 1988;108:71-81.
85. Wiener E, McGuire P, Stolar C, RIch H, Albo V, Ablin AR, et al.The CCSG prospective study of venous access devices: an analysis of insertions and causes for removal. Journal of Pediatric Surgery 1992;27(2):155-64.
86. Wiernikowski JT, Elder-Thornley D, Dawson S, Rothney M, Smith S. Bacterial colonization of tunneled right atrial catheters in pediatric oncology: a comparison of sterile saline and bacteriostatic saline flush solutions. American Journal of Pediatric Hematologogy/Oncology 1991;13:137-40.
87. Adler A, Yaniv I, Steinberg R, Solter E, Samra Z, Stein J, et al.Infectious complications of implantable ports and Hickman catheters in paediatric haematology-oncology patients. Journal of Hospital Infection 2006;62(3):358-65.
88. Bagnall-Reeb H. Evidence for the use of the antibiotic lock technique. Journal of Infusion Nursing 2004;27(2):118-22.
89. Barbaric D, Curtin J, Pearson L, Shaw PJ. Role of hydrochloric acid in the treatment of central venous catheter infections in children with cancer. Cancer 2004;101:1866-72.
90. Bell AL, Jayaraman R, Vercaigne LM. Effect of ethanol/trisodium citrate lock on the mechanical properties of carbothane hemodialysis catheters. Clinical Nephrology 2006;65(5):342-8.
91. Bernardi M, Cavaliere M, Cesaro S. The antibiotic-lock therapy in oncoematology pediatric unit [L'uso dell'antibiotic-therapy in un reparto di oncoematologia pediatrica]. Assistenza Infermieristica e Ricerca 2005;24(3):127-31.
92. Bradshaw JH, Puntis JWL. Taurolidine and catheter-related bloodstream infection: a systematic review of literature. Journal of Pediatric Gastroenterology and Nutrition 2008;47:179-86.
93. Carratala J. The antibiotic-lock technique for therapy of 'highly needed' infected catheters. Clinical Microbiology and Infection 2002;8(5):282-9.
94. Cesaro S, Corro R, Pelosin A, Gamba P, Zadra N, Fusaro F, et al.A prospective survey on incidence and outcome of Broviac/Hickman catheter-related complications in pediatric patients affected by hematological and oncological diseases. Annals of Hematology 2004;83(3):183-8.
95. Cesaro S, Cavaliere M, Spiller M, Rossi L, Magagna L, Gavin P, et al.A simplified method of antibiotic lock therapy for Broviac-Hickman catheters using a CLC 2000 connector device. Supportive Care in Cancer 2007;15:95-9.
96. Chaudhury A, Rangineni J, Venkatramana B. Catheter lock technique: in vitro efficacy of ethanol for eradication of methicillin-resistant staphylococcal biofilm compared with other agents. FEMS Immunology and Medical Microbiology 2012;65:305-8.
97. Chu HP, Brind J, Tomar R, Hill S. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock. Journal of Pediatric Gastroenterology and Nutrition 2012;55(4):403-7.
98. Cober MP, Kovacevich DS, Teitelbaum DH. Ethanol-lock therapy for the prevention of central venous access device infections in pediatric patients with intestinal failure. Journal of Parenteral and Enteral Nutrition 2011;35(1):67-73.
99. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org, 2011.
100. Costa SF, Miceli MH, Anaissie EJ. Mucosa or skin as source of coagulase-negative staphylococcal bacteraemia?. Lancet Infectious Diseases 2004;4:278-86.
101. Cuntz D, Michaud L, Guimber D, Husson MO, Gottrand F, Turck D. Local antibiotic lock for the treatment of infections related to central catheters in parenteral nutrition in children. Journal of Parenteral and Enteral Nutrition 2002;26(2):104-8.
102. De Sio L, Jenkner A, Milano GM, Ilari I, Fidani P, Castellano A, et al.Antibiotic lock with vancomycin and urokinase can successfully treat colonized central venous catheters in pediatric cancer patients. Pediatric Infectious Disease Journal 2004;23(10):963-5.
103. Droste JC, Jeraj HA, MacDonald A, Farrington A. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. Journal of Antimicrobial Chemotherapy 2003;51:849-55.
104. Dümichen MJ, Seeger K, Lode HN, Kühl JS, Ebell W, Degenhardt P, et al.Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies. Journal of Hospital Infection 2012;80:304-9.
105. Eggiman P, Sax H, Pittet D. Catheter-related infections. Microbes and Infection 2004;6:1033-42.
106. Fleischhack G, Schmidt-Niemann M, Wulff B, Havers W, Marklein G, Hasan C, et al.Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Supportive Care in Cancer 2001;9(5):372-9.
107. Fleischhack G, Hartmann C, Simon A, Wulff B, Havers W, Marklein G, et al.Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. Journal of Antimicrobial Chemotherapy 2001;47(6):841-53.
108. Flynn PM. Diagnosis, management and prevention of catheter-related infections. Seminars in Pediatric Infectious Diseases 2000;11(2):113-21.
109. Franklin JA, Gaur AH, Shenep JL, Hu XJ, Flynn PM. In situ diagnosis of central venous catheter-related bloodstream infection without peripheral blood culture. Pediatric Infectious Disease Journal 2004;23(7):614-8.
110. Fratino G, Molinari AC, Parodi S, Long S, Saracco P, Castagnola E, et al.Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. Annals of Oncology 2005;16(4):648-54.
111. Hachem R, Raad I. Prevention and management of long-term catheter related infections in cancer patients. Cancer Investigation 2002;20(7-8):1105-13.
112. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). British Journal of Haematology 1997;99(3):580-8.
113. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
114. Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatric Infectious Disease Journal 1994;13(10):930-1.
115. Jones GR, Konsler GK, Dunaway RP, Lacey SR, Azizkhan RG. Prospective analysis of urokinase in the treatment of catheter sepsis in pediatric hematology-oncology patients. Journal of Pediatric Surgery 1993;28:350-5.
116. Jones GR, Konsler GK, Dunaway RP. Urokinase in the treatment of bacteremia and candidemia in patients with right atrial catheters. American Journal of Infection Control 1996;24:160-6.
117. Jones BA, Hull MA, Richardson DS, Zurakowski D, Gura K, Fitzgibbons SC, et al.Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure. Journal of Pediatric Surgery 2010;45:1287-93.
118. Kayton ML, Garmey EG, Ishill NM, Cheung NV, Kushner BH, Kramer K, et al.Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections. Journal of Pediatric Surgery 2010;45:1961-66.
119. Koldehoff A, Zakrzewski JL. Taurolidine is effective in the treatment of central venous catheter-related bloodstream infections in cancer patients. International Journal of Antimicrobial Agents 2004;24(5):491-5.
120. Laird J, Soutar R, Butcher I. Complications of the ethanol-lock technique in the treatment of central venous catheter sepsis. Journal of Infection 2005;51:338-41.
121. Maiefski M, Rupp ME, Hermsen ED. Ethanol lock technique: review of the literature. Infection Control and Hospital Epidemiology 2009;30:1096-108.
122. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: A systematic review of 200 published prospective studies. Mayo Clinic Proceedings 2006;81(9):1159-71.
123. McCarthy A, Byrne M, Breatnach F, O'Meara A. "In-situ" Teicoplanin for central venous catheter infection. Irish Journal of Medical Sciences 1995;164:125-7.
124. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, et al.Guidelines for the management of intravascular catheter-related infections. Infection Control and Hospital Epidemiology 2001;22(4):222-42.
125. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al.IDSA Guidelines for the diagnosis and management of intravascular catheter-related bloodstream infection reply. Clinical Infectious Diseases 2009;49(11):1771-2.
126. Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ. Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. Journal of Parenteral and Enteral Nutrition 1988;12(2):185-9.
127. Kremer LCM, van Dalen EC, Moher D, Caron HN. Cochrane Childhood Cancer Group. The Cochrane Library. Chichester: Wiley-Blackwell, 2010:issue 4.
128. Mouw E, Chessman K, Leshner A, Tagge E. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. Journal of Pediatric Surgery 2008;43:1025-9.
129. O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG, et al.Guidelines for the prevention of intravascular catheter-related infections. Clinical Infectious Diseases 2002;35(11):1281-307.
130. Oliveira C, Nasr A, Brindle M, Wales PW. Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: a meta-analysis. Pediatrics 2012;129:1-12.
131. Onland W, Shin CE, Fustar S, Rushing T, Wong WY. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Archives of Pediatrics and Adolescent Medicine 2006;160(10):1049-53.
132. Plourde R, Gothard D, Markowski A, Cockrell E. Efficacy of ethanol locks for treatment of central venous catheter infections in pediatric oncology patients. 24th Annual Meeting of the American Society of Pediatric Hematology Oncology, ASPHO. 2011:940.
133. Qu Y, Istivan TS, Daley AJ, Rouch DA, Deighton MA. Comparison of various antimicrobial agents as catheter lock solutions: preference for ethanol in eradication of coagulase-negative staphylococcal biofilms. Journal of Medical Microbiology 2009;58:442-50.
134. Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey GP. Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. The Journal of Infectious Diseases 1993;168(2):400-7.
135. Rane HS, Bernardo SM, Walraven CJ, Lee SA. In vitro analyses of ethanol activity against Candida albicans biofilms. Antimicrrobial Agents and Chemotherapy 2012;56(8):4487-9.
136. Rao JS, O'Meara A, Harvey T, Breatnach F. A new approach to the management of Broviac catheter infection. Journal of Hospital Infections 1992;22:109-16.
137. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. Journal of Antimicrobial Chemotherapy 2005;55(1):90-4.
138. Rotstein C, Brock L, Roberts RS. The incidence of first Hickman catheter-related infection and predictors of catheter removal in cancer-patients. Infection Control and Hospital Epidemiology 1995;16(8):451-8.
139. Sanders J, Pithie A, Ganly P, Surgenor L, Wilson R, Merriman E, et al.A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. Journal of Antimicrobial Chemotherapy 2008;62:809-15.
140. Segarra-Newnham M, Martin-Cooper EM. Antibiotic lock technique: A review of the literature. Annals of Pharmacotherapy 2005;39(2):311-8.
141. Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH. Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infection Control and Hospital Epidemiology 2000;21(9):592-6.
142. Slobbe L, Doorduijn JK, Lugtenburg PJ, El Barzouhi A, Boersma E, van Leeuwen WB, et al.Prevention of catheter-related bacteremia with daily ethanol lock in patients with tunnelled catheters: a randomized, placebo-controlled trial. PLoS ONE 2010;5(5):e10840.
143. Torres-Viera C, Thauvin-Eliopoulos C, Souli M, De Girolami P, Farris MG, Wennersten CB, et al.Acitivities of taurolidine in vitro and in experimental enterococcal endocarditis. Antimicrobial Agents and Chemotherapy 2000;44(6):1720-4.
144. van de Wetering MD, van Woensel JB. Prophylactic antibiotics for preventing early central venous catheter Gram positive infections in oncology patients. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD003295.pub2]
145. Wales PW, Kosar C, Carricato M, De Silva N, Lang K, Avitzur Y. Ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients with intestinal failure: preliminary experience. Journal of Pediatric Surgery 2011;46:951-6.
146. Yazici N, Akyüz C, Küpeli S, Demir A, Büyükpamukçu M. Antibiotic lock therapy in central venous catheters. 39th Congress of the International Society of Pediatric Oncology, SIOP. 2007:514.